These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34735255)

  • 1. RNA drugs custommade for rare diseases face wider test.
    Kaiser J
    Science; 2021 Nov; 374(6568):672. PubMed ID: 34735255
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges in orphan drug development and regulatory policy in China.
    Cheng A; Xie Z
    Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals.
    Velho RV; Sperb-Ludwig F; Schwartz IV
    An Acad Bras Cienc; 2015 Aug; 87(2 Suppl):1375-88. PubMed ID: 26247150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal therapy for rare disorders and genetic diseases: ethical and political challenges.
    MacLeod S
    Proc West Pharmacol Soc; 2007; 50():21-3. PubMed ID: 18605224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-targeting pharmaceuticals for single-gene disorders.
    Beaudet AL; Meng L
    Hum Mol Genet; 2016 Apr; 25(R1):R18-26. PubMed ID: 26628634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing drugs for rare genetic diseases: trends and insights.
    Zitter M
    Manag Care; 2005 Feb; 14(2):52-4, 57-60, 63-4; quiz 66-7. PubMed ID: 15782848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery and development for rare genetic disorders.
    Sun W; Zheng W; Simeonov A
    Am J Med Genet A; 2017 Sep; 173(9):2307-2322. PubMed ID: 28731526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lp(a)-lowering drugs bolster cardiovascular pipeline.
    Dolgin E
    Nat Rev Drug Discov; 2020 Mar; 19(3):154-155. PubMed ID: 32127677
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug repositioning can accelerate discovery of pharmacological chaperones.
    Hay Mele B; Citro V; Andreotti G; Cubellis MV
    Orphanet J Rare Dis; 2015 May; 10():55. PubMed ID: 25947946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Which efficacy trials for drugs for rare diseases?].
    Traversa G; Trotta F
    Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
    Gobburu J; Pastoor D
    Clin Pharmacol Ther; 2016 Oct; 100(4):322-3. PubMed ID: 27326701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare genetic diseases: update on diagnosis, treatment and online resources.
    Pogue RE; Cavalcanti DP; Shanker S; Andrade RV; Aguiar LR; de Carvalho JL; Costa FF
    Drug Discov Today; 2018 Jan; 23(1):187-195. PubMed ID: 29129805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A generalizable pre-clinical research approach for orphan disease therapy.
    Beaulieu CL; Samuels ME; Ekins S; McMaster CR; Edwards AM; Krainer AR; Hicks GG; Frey BJ; Boycott KM; Mackenzie AE
    Orphanet J Rare Dis; 2012 Jun; 7():39. PubMed ID: 22704758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market watch: Upcoming market catalysts in Q1 2016.
    Inui E
    Nat Rev Drug Discov; 2016 Jan; 15(1):9. PubMed ID: 26678618
    [No Abstract]   [Full Text] [Related]  

  • 15. Technology evaluation: ISIS-113715, Isis.
    Liu G
    Curr Opin Mol Ther; 2004 Jun; 6(3):331-6. PubMed ID: 15264436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare diseases and orphan drugs.
    Melnikova I
    Nat Rev Drug Discov; 2012 Mar; 11(4):267-8. PubMed ID: 22460117
    [No Abstract]   [Full Text] [Related]  

  • 17. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 18. 2-5A antisense treatment of respiratory syncytial virus.
    Leaman DW
    Curr Opin Pharmacol; 2005 Oct; 5(5):502-7. PubMed ID: 16081320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating access to treatments for rare diseases.
    Dunoyer M
    Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery.
    Chen B; Altman RB
    Orphanet J Rare Dis; 2017 Apr; 12(1):61. PubMed ID: 28412959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.